MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech in a Minute: Hologic's Cynosure Flop, Axonics Stands Its Ground, and More

Hologic's Cynosure business was a letdown, and a huge diagnostics deal may be in the works. But first, Axonics holds its own against Medtronic.

Pressed for time? Here's the medtech news you need most, in one minute or less.

Image by OpenClipart-Vectors on Pixabay

Axonics Not Intimidated by Medtronic

Axonics' implantable rechargeable sacral neuromodulation device is now FDA-approved for the treatment of fecal incontinence, overactive bladder, and urinary retention. Medtronic is suing Axonics for alleged patent infringement, but the company does not appear to be intimidated.

 

Thermo Fisher May Fancy Qiagen

The rumor mill was lit with a recent Bloomberg report of a potential $8 billion Thermo Fisher-Qiagen deal. Qiagen acknowledged that it has received several "indications of interest" but the company stopped short of revealing the potential buyers.

Cynosure Turns Out to Be More Beast Than Beauty

Hologic dropped $1.65 billion on Cynosure two years ago, but the company has struggled with the business since the beginning and is now throwing in the towel. Cynosure will be acquired by an affiliate of investment funds managed by Clayton, Dubilier & Rice for $205 million.

Filed Under
500 characters remaining